Detail
| LncRNA Name | AB209630 |
| Synonyms | NA |
| Region | GRCh38_9:69248696-69251364 Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 M8500/3 |
| Methods | qPCR, Western blot |
| Sample | pancreatic ductal adenocarcinoma tissues, cell lines (Panc-1 and BXPC-3) |
| Expression Pattern | down-regulated |
| Function Description | increased expression of lncRNA AB209630 could suppress cell proliferation and cell colony formation ability in gemcitabine resistance cells of PDAC. upregulation of lncRNA AB209630 suppressed the PI3K/AKT signaling pathway in gemcitabine resistance cells.lncRNA AB209630 expression was dramatically downregulated in PDAC tissues compared to adjacent normal tissues. Lower PDAC expression predicted a poor prognosis in PDAC patients. lncRNA AB209630 expression associated 184 with poor overall survival time. |
| Pubmed ID | 29526843 |
| Year | 2018 |
| Title | LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma. |
| External Links |
| Links for AB209630 | GenBank HGNC lncrnadb Noncode |
| Links for pancreatic ductal adenocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.